Not a bad quarter.
Higher cash burn due to stocking of HighRise with expected increased demand particularly through Stryker.
I was really keen to see if there were any sales through Stryker as so many other companies have similar sorts of deals and they never happen or its a trickle. Looks like the Stryker deal is a real goer and sets up Curvbeam well.
Curvebeam seems to be streets ahead of 4DX which has really struggled to get any sales in the USA. The fact that Curvebeam is eligible for reimbursement is a huge advantage.
They have stated they are fully funded for 24 months.
Curvebeam could be the next big medtech growth stock listed on the ASX.
A couple more increasingly good quarters and positive market sentiment and this could really take off.
Ann: Quarterly Activities Webinar Presentation - Sep 2023 Qtr, page-3
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CVB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.005(2.70%) |
Mkt cap ! $41.54M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 19.0¢ | $1.108K | 5.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 6457 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.0¢ | 2770 | 1 |
View Market Depth
| Last trade - 15.35pm 04/07/2024 (20 minute delay) ? |
| CVB (ASX) Chart |